First-In-Human Study in Participants With Advanced Solid Tumors
ConditionAdvanced Solid Tumors
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorChengdu Kanghong Biotech Co., Ltd.
About this trial
A Phase 1 Study of KH815 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients with Advanced Solid Tumors
Eligibility criteria
Qualifiers
Signed, written IRB-approved Informed Consent.
Male or female.
Aged 18 ~ 75 years.
Life expectancy of at least 3 months.
Disqualifiers
Pregnant or lactating women.
Major surgery within 4 weeks or will be expected to require major surgical treatment during the study period.
Radical radiotherapy or chest palliative radiotherapy within 4 weeks, or palliative radiotherapy at any other sites except chest within 2 weeks.
Antibody-based anti-cancer therapies, macromolecular protein products or cytotherapies within 4 weeks.
Trial design
Treatments tested in this trial
- KH815 for injection
Treatment groups
30 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov